Related Experiment Video
Updated: Jul 14, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
Published on: October 17, 2013
[Evaluation of ultramicroporous expanded polytetrafluoroethylene mitral valve under pulsatile flow condition in
Yong Liang1, Wu-jun Wang, Kai-can Cai
1Department of Cardiothoracic Surgery, 454 Hospital of PLA, Nanjing 210002, China. b.z.liang@163.com
Objective:
To test 25# and 27# ultramicroporous expanded polytetrafluo-roethylene mitral valve (UPMV) under pulsatile flow condition in vitro.
Methods:
Six 25# and six 27#UPMV were tested using TH-1200 HV Prosthesis Pulsatile Flow Tester in vitro at the cycling rate of 70 cycle/min, with the systolic pressure maintained at about 16 kPa (120 mmHg), diastolic pressure at 10.7 kPa (80 mmHg), and the percentage of mean forward flow at 35%. The stimulant cardiac output was maintained at 2, 3, 4, 5 and 6 L/min, respectively, for the testing.
Results:
The mean pressure difference for the 25#UPMV under stimulant cardiac output of 2, 3, 4, 5 and 6 L/min was 2.488-/+0.378, 4.427-/+0.240, 5.460-/+0.449, 6.776-/+0.391 and 8.327-/+0.490 mmHg, and its effective valvular orifice was 1.430-/+0.333, 1.993-/+0.208, 2.260-/+0.477, 3.204-/+0.174 and 3.652-/+0.158 cm(2), respectively. The regurgitant fraction of the 25#UPMV under each stimulant cardiac output was (5.731-/+0.643) %, (5.431-/+0.312) %, (5.059-/+0.708) %, (3.545-/+0.097) % and (2.615-/+0.125) %, respectively. The mean pressure difference of the 27#UPMV under each stimulant cardiac output was 1.618-/+0.497, 3.448-/+0.440, 4.825-/+0.434, 5.494-/+0.446 and 7.482-/+0.455 mmHg, effective valvular orifice was 1.773-/+0.364, 2.113-/+0.305, 2.409-/+0.295, 3.326-/+0.417 and 4.522-/+0.445 cm(2), and regurgitant fraction was (5.357-/+0.509) %, (5.407-/+0.110) %, (4.999-/+0.182) %, (4.010-/+0.254) % and (2.584-/+0.114)%, respectively.
Conclusion:
The mean pressure difference, effective valvular orifice and regurgitant fraction of the UPMVs can measure up to the national criteria for artificial heart valve prosthesis of China.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
